bioLive is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dr. Tae Han Kim has been Chief Executive Officer at Samsung BioLogics since the Samsung group diversified into the pharmaceutical business as the new growth engine for the next generation in April, 2011. Dr. Kim brings to biopharma industry innovative construction and operation know-hows through his extensive experience in various industries including electronics and petrochemical. Dr. Kim began his career with Samsung in 1979. Prior to joining Samsung BioLogics,
Dr. Kim served as Executive Vice President of Strategic Business Development at Samsung Group and held a senior leadership position for Samsung Total Petrochemicals, a joint venture company between Total of France and Samsung. While he led task force team to find Samsung group’s next growth engine, he saw the biopharma industry generally and the CMO space specifically in sustained growth pattern. Dr. Kim convinced Samsung Group to invest about $3 billion in the biopharma industry. Dr. Kim holds a doctoral degree in chemical engineering from the University of Texas at Austin.